NCT04347616 2026-03-16
NK4AML
Radboud University Medical Center
Phase 1/2 Terminated
Clinical Trials
38 trialsNCT05639972 2026-02-27
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
Phase 1/2 Recruiting
NCT07389239 2026-02-20
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
Phase 1/2 Not yet recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting
NCT05821686 2025-02-12
Efficacy of Interleukin-2 in Triple Negative Breast Cancer
Nova Scotia Health Authority
Phase 1/2 Not yet recruiting
NCT03318900 2024-11-07
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT01740557 2024-10-08
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03658785 2024-08-13
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
Phase 1/2 Recruiting
NCT01898793 2024-01-17
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
Phase 1/2 Terminated
NCT06152367 2023-11-30
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
University of Chile
Phase 1/2 Completed
NCT01823198 2023-11-07
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01640301 2022-07-14
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02770820 2021-10-29
Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02408016 2021-09-13
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01701479 2020-07-14
LTI
St. Anna Kinderkrebsforschung
Phase 1/2 Unknown
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT02173093 2019-01-29
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
University of Virginia
Phase 1/2 Unknown
NCT00303667 2017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed
NCT00625729 2017-12-28
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01758458 2017-04-19
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT00052520 2017-03-29
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00553306 2017-02-15
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00937625 2015-08-18
T-cell Based Immunotherapy for of Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00003585 2013-12-10
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
University of New Mexico
Phase 1/2 Completed
NCT00003356 2013-10-16
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
University of Rochester
Phase 1/2 Completed
NCT00003229 2013-03-25
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
Duke University
Phase 1/2 Completed
NCT01409187 2012-01-26
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00002681 2011-06-10
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Roger Williams Medical Center
Phase 1/2 Completed
NCT00248430 2010-09-21
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00002786 2010-05-10
Biological Therapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00197912 2010-04-26
Dendritic Cell Based Therapy of Malignant Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00005802 2010-04-02
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Completed